Investigational Drug Information for Ladarixin
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for Ladarixin?
Ladarixin is an investigational drug.
There have been 6 clinical trials for Ladarixin.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 21st 2020.
The most common disease conditions in clinical trials are Diabetes Mellitus, Type 1, Diabetes Mellitus, and Insulin Resistance. The leading clinical trial sponsors are Dompé Farmaceutici S.p.A and [disabled in preview].
There are ten US patents protecting this investigational drug and eighty-six international patents.
Summary for Ladarixin
| US Patents | 10 |
| International Patents | 86 |
| US Patent Applications | 47 |
| WIPO Patent Applications | 39 |
| Japanese Patent Applications | 15 |
| Clinical Trial Progress | Phase 2 (2020-12-21) |
| Vendors | 15 |
Recent Clinical Trials for Ladarixin
| Title | Sponsor | Phase |
|---|---|---|
| Randomized, Double-blind, Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes. | Dompé Farmaceutici S.p.A | Phase 2 |
| Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes | Dompé Farmaceutici S.p.A | Phase 2 |
| A Study of Oral Ladarixin in New-onset Type 1 Diabetes and a Low Residual β-cell Function | Dompé Farmaceutici S.p.A | Phase 3 |
Clinical Trial Summary for Ladarixin
Top disease conditions for Ladarixin
Top clinical trial sponsors for Ladarixin
US Patents for Ladarixin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ladarixin | See Plans and Pricing | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | See Plans and Pricing |
| Ladarixin | See Plans and Pricing | Oral drug dosage forms having desired drug release profiles and uses thereof | Triastek, Inc. (Nanjing, CN) | See Plans and Pricing |
| Ladarixin | See Plans and Pricing | Soluble C5aR antagonists | ChemoCentryx, Inc. (Mountain View, CA) | See Plans and Pricing |
| Ladarixin | See Plans and Pricing | Compartmented pharmaceutical dosage forms | Triastek, Inc. (Nanjing, CN) | See Plans and Pricing |
| Ladarixin | See Plans and Pricing | Soluble C5aR antagonists | ChemoCentryx, Inc. (Mountain View, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ladarixin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ladarixin | Australia | AU2017261372 | 2036-05-05 | See Plans and Pricing |
| Ladarixin | Canada | CA3023278 | 2036-05-05 | See Plans and Pricing |
| Ladarixin | China | CN107847398 | 2036-05-05 | See Plans and Pricing |
| Ladarixin | European Patent Office | EP3452003 | 2036-05-05 | See Plans and Pricing |
| Ladarixin | European Patent Office | EP3981392 | 2036-05-05 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
